%0 Case Reports
%T PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature.
%A Wang Z
%A Zeng T
%A Li Y
%A Zhang D
%A Yuan Z
%A Huang M
%A Yang Y
%A Zhou W
%J Front Immunol
%V 12
%N 0
%D 2021
%M 35003124
%F 8.786
%R 10.3389/fimmu.2021.799822
%X Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer with a poor prognosis. Recently, an immunotherapy strategy represented by programmed cell death 1 (PD-1) inhibitors has been applied to the systemic treatment of advanced iCCA. However, immunotherapy combined with chemotherapy as first-line maintenance therapy was rarely reported. Our report presented an advanced iCCA patient who had a dramatic response to the PD-1 inhibitor sintilimab combined with gemcitabine plus cisplatin as the first-line therapy and sintilimab combined with capecitabine as maintenance therapy, yielding an ongoing progression-free survival of 16 months.